Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults
The New England Journal of Medicine
•
May 07, 2026
Messenger RNA flu vaccine reduced flu-like illness
In adults aged 50 years or older, a messenger RNA seasonal influenza vaccine prevented more lab-confirmed influenza-like illness than a standard-dose licensed vaccine, but caused more short-term side effects. *Randomized double-blind trial; Level 1b (OCEBM).
- Level of evidence
- Level 1b (OCEBM)
- DocG quality score
- 6.7 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
